Company Overview
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.
Why Investors Should Care
Revenue has grown at a 84.5% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $34.51M (+37.0% YoY); net profit $-11.13M.
- Trailing 12 Months Year-on-year growth — revenue +3.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 84.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 84.46% |
| 1 Year: | 3.80% |
Stock Price Performance
| 1 Year: | -80.93% |
| 6 Months: | -57.01% |
| 3 Months: | -41.99% |
| 1 Month: | -29.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 84.5% over 5 years.
CONS
- Trading 85.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BHST BioHarvest Sciences Inc. | 1.81 | -3.55 | $41.03M | 0.00% | -13.94% | -142.50% | 84.46% | - |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 38.82 | $850.02B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 910.18 | 45.88 | $403.65B | 0.65% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.36 | 26.53 | $380.17B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 145.58 | 21.99 | $338.39B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 184.73 | 25.37 | $287.92B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.45 | 18.15 | $189.12B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 79.73 | 17.18 | $139.30B | 1.69% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | BTI British American Tobacco p.l.c. | 55.15 | 14.18 | $118.73B | 5.98% | 12.44% | 13.42% | -2.53% | 5.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 7.86M | 8.52M | 9.07M | 9.07M | 8.51M |
| Cost of Revenue | 3.27M | 3.43M | 3.50M | 3.84M | 3.47M |
| Gross Profit | 4.59M | 5.09M | 5.57M | 5.22M | 5.04M |
| Operating Expenses | 6.31M | 6.90M | 6.49M | 6.35M | 6.87M |
| Operating Income | -1.72M | -1.81M | -920.00K | -1.12M | -1.83M |
| EBITDA | -1.32M | -1.41M | -535.00K | -3.45M | -1.29M |
| Interest Expense | 581.00K | 2.23M | 1.53M | -1.61M | 875.00K |
| Pretax Income | -2.30M | -4.04M | -2.45M | -2.27M | -2.60M |
| Tax Provision | 38.00K | 39.00K | 63.00K | -64.00K | 46.00K |
| Net Income | -2.34M | -4.08M | -2.51M | -2.20M | -2.64M |
| Diluted EPS | -0.13 | -0.24 | -0.14 | - | -0.11 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 5.50M | 12.67M | 25.19M | 34.51M |
| Cost of Revenue | - | 4.28M | 7.04M | 11.25M | 14.03M |
| Gross Profit | - | 1.22M | 5.63M | 13.94M | 20.48M |
| Operating Expenses | - | 11.83M | 15.60M | 20.93M | 26.05M |
| Operating Income | - | -10.61M | -9.97M | -6.99M | -5.58M |
| EBITDA | - | -9.12M | -9.76M | -6.92M | -6.71M |
| Interest Expense | - | 1.40M | 1.96M | 4.74M | 2.72M |
| Pretax Income | - | -11.24M | -12.56M | -12.90M | -11.06M |
| Tax Provision | - | - | 0 | 8.00K | 76.00K |
| Net Income | - | -11.24M | -12.56M | -12.91M | -11.13M |
| Diluted EPS | - | -0.70 | -0.93 | -0.80 | -0.60 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 9.39M | 15.00M | 25.00M | 47.66M |
| Current Assets | - | 4.32M | 9.05M | 7.86M | 30.50M |
| Cash & Equivalents | - | 1.74M | 5.36M | 2.39M | 23.02M |
| Inventory | - | 1.38M | 2.47M | 3.65M | 4.56M |
| Receivables | - | 545.00K | 808.00K | 1.12M | 1.98M |
| Total Liabilities | - | 15.32M | 29.86M | 23.67M | 22.22M |
| Current Liabilities | - | 11.52M | 26.47M | 14.26M | 7.68M |
| Long Term Debt | - | - | - | - | 2.42M |
| Total Debt | - | 10.56M | 22.34M | 13.82M | 14.10M |
| Total Equity | - | -5.93M | -14.85M | 1.33M | 25.45M |
| Shares Outstanding | - | 13.16M | 13.68M | 17.33M | 22.67M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.24M | -8.52M | -6.68M | -7.23M |
| Investing Cash Flow | - | -1.26M | -1.47M | -3.03M | -2.37M |
| Financing Cash Flow | - | 8.14M | 13.56M | 6.78M | 30.19M |
| Capital Expenditure | - | -1.26M | -1.47M | -2.83M | -2.35M |
| Free Cash Flow | - | -10.50M | -10.00M | -9.52M | -9.58M |
| Net Change in Cash | - | -2.36M | 3.56M | -2.93M | 20.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 22.2% | 44.5% | 55.4% | 59.3% |
| Operating Margin % | - | -193.0% | -78.6% | -27.7% | -16.2% |
| Net Margin % | - | -204.4% | -99.1% | -51.3% | -32.3% |
| ROE % | - | 189.5% | 84.6% | -970.9% | -43.8% |
| ROCE % | - | 499.2% | 86.9% | -65.1% | -13.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 3.54% | 581.44K | $947.75K |
| 2 | Thompson, Siegel & Walmsley LLC | 2.22% | 364.01K | $593.33K |
| 3 | Evercore Wealth Management, LLC | 1.32% | 216.34K | $352.64K |
| 4 | True North Advisors, LLC | 1.14% | 187.32K | $305.33K |
| 5 | Magnus Financial Group LLC | 0.55% | 90.00K | $146.70K |
| 6 | Susquehanna International Group, LLP | 0.39% | 63.66K | $103.76K |
| 7 | Silverberg Bernstein Capital Management LLC | 0.35% | 57.72K | $94.09K |
| 8 | King Luther Capital Management | 0.24% | 40.00K | $65.20K |
| 9 | TD Waterhouse Canada Inc. | 0.15% | 23.83K | $38.84K |
| 10 | Citadel Advisors Llc | 0.13% | 20.65K | $33.66K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHST
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOMUk2bzc0dGFjRkd2b193aW96R3JycEpuTzJwcERVUC1kMzdPTHZCUWJpaEdjUm56WWFPVHBDYmtReUVOQ0pXR1lGdWRnMUpfbl90MS1leTFwMVExY3pWNkFuQjJjbjVIc2ZZY1pxMU03Z3FfczJDem1KcDg4TUdnNVE3N2hQYnFacWlKUD…
BioHarvest seeks to put 22.7 million shares on Israel’s stock exchange - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQYUF6Tk9pV1B5M0djVXEwZlpPdXRGVXhKanVQV2ItbklMT2NILXdhUUZzcUpOUUc1eG9WRXB0R09fRlZxWGVyR3FOUzJaa2toTklxMkdJcEZXSmZDa3JTdjJkRjFVVjB4N0pwNWV4RlhWTUg0TFNWaE9rTmtvUlhtejhYMW1yelNrSU9hLU…
BioHarvest Sciences plans Tel Aviv Stock Exchange dual listing - Proactive financial news
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNTGlsRVVwbU0zb3JhMFRRVVhuVG4ySkFHMDBrTEdPZUFIcF9jT0c3VTNKTDVVQzVxbHJ4d1NzdXdHWFZLaUthWTk5TWNjUDdPV2h5b2xlRjNmZ2dHTU5jV0NwdkdRdFMwZW1UZnprSEtMZlUxWTdPNGJXb1loM3hBMThpbVkxNkZYR2Y2ZF…
Tel Aviv listing on deck for BioHarvest (NASDAQ: BHST). Trading is expected to start in 2026. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMmFiSk0zTDNHMVNtYV82VEhPeERjVkM5dnZPaTNpWjJJcUlkcDBwRzZiZnVmR0g0U29Pa044T0h3T2VVSkFVQlkyRkxIT0lERzlhTU1lb0JxSEVjUjNwMUcxcXZhSFA5bkdOc1FncGVRV21SYzBpRm1rR2NZOURaSDZyQ1UwWXliQzFmb0…
Market Sentiment Around Loss-Making BioHarvest Sciences Inc. (NASDAQ:BHST) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNWmRrRmFNU2JNQ0JwSE5YTmwwTVZiMUF1NUpQSUZ4VmlwNFI4NFFQT2R4VnZOYkJ5cFpTeVV2c09IVkYzc2JTcFo3UmZHUkxzeVJneVdGUTF3SmJIZnFJU2NFa0xJeTRLeV9HSjBHUkdYSm5HcjVsc0JZWjBISnpPX0llUGpBY2Y5ZG01am…
BioHarvest Sciences Inc. (NASDAQ: BHST) to Initiate Dual Listing on Tel Aviv Stock Exchange for 22.7M Shares - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNMHlEbXpCa1VuV2t6SWo1X1cyWGhCQWctX1JpbC1BMmcxYWRtVXRiSFdYbVR4U0ZTV3RCV2pBRE9HenV6dG0xRjQ0ZUdNSEdCU1pLdzB1WE4yOGUySUdBT245VWphVGhFdDNQcG5YZlB1S21oaDF3akVfcDNBbFhsbVNwMmtoVTd5cnhIU1…
BHST — Frequently Asked Questions
What is the current share price of BioHarvest Sciences Inc. (BHST)?
As of 2026-09-19 21:16 PDT, BioHarvest Sciences Inc. (BHST) trades at $1.81 on NasdaqGM. Its 52-week range is $1.80 to $12.65.
What is the market capitalisation of BHST?
BioHarvest Sciences Inc. (BHST) has a market capitalisation of $41.03M on NasdaqGM.
What is the P/E ratio of BHST?
BHST trades at a trailing price-to-earnings (P/E) ratio of -3.55. The industry average P/E is 18.56. Its price-to-book (P/B) ratio is 2.06.
What is the return on equity (ROE) of BHST?
BHST has a return on equity (ROE) of -142.50%. Its return on capital employed (ROCE) is -13.94%.
Is BHST a good stock to buy?
This page provides a data-driven analysis of BioHarvest Sciences Inc. (BHST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.